Familial Hypocalciuric Hypercalcemia

Familial Hypocalciuric Hypercalcemia (FHH): The Definitive Clinical Guide

Familial Hypocalciuric Hypercalcemia (FHH) is a rare, benign, autosomal dominant genetic disorder characterized by lifelong asymptomatic hypercalcemia, inappropriately normal or elevated parathyroid hormone (PTH) levels, and low urinary calcium excretion. Often mistaken for Primary Hyperparathyroidism (PHPT), FHH is a condition where the "set-point" of the calcium-sensing receptor (CaSR) is shifted, leading the body to perceive high serum calcium levels as normal.

Understanding FHH is paramount for clinicians, specifically endocrinologists and surgeons, to avoid unnecessary and potentially harmful parathyroidectomies. This guide provides an exhaustive clinical overview of the condition.

1. Etiology and Pathophysiology: The Molecular Mechanism

The hallmark of FHH is an alteration in the body’s "calciostat." Under normal physiological conditions, the Calcium-Sensing Receptor (CaSR)—a G-protein coupled receptor expressed primarily in the parathyroid glands and the renal tubules—monitors serum ionized calcium.

The CaSR Mechanism

• Parathyroid Glands: When serum calcium is high, the CaSR detects it and suppresses PTH secretion. In FHH, the receptor is "blind" or less sensitive, requiring a higher calcium concentration to trigger the same suppression.
• Renal Tubules: In the kidneys, the CaSR regulates calcium reabsorption. In FHH, the receptor’s altered sensitivity leads to increased calcium reabsorption in the thick ascending limb of the loop of Henle, resulting in the characteristic hypocalciuria.

Genetic Basis

FHH is categorized into three distinct genetic types:
1. FHH Type 1 (Most common): Caused by heterozygous inactivating mutations in the CASR gene on chromosome 3q21.1.
2. FHH Type 2: Caused by mutations in the GNA11 gene, which encodes the G-protein alpha-11 subunit that links the CaSR to intracellular signaling.
3. FHH Type 3: Caused by mutations in the AP2S1 gene, which encodes the adaptor protein-2 sigma subunit, interfering with the trafficking of the CaSR to the cell surface.

2. Clinical Presentation and Diagnostic Criteria

Patients with FHH are almost universally asymptomatic. Unlike PHPT, which may present with "bones, stones, abdominal groans, and psychic moans," FHH patients rarely report clinical complications related to hypercalcemia.

Standard Clinical Indicators

• Persistent Hypercalcemia: Usually detected incidentally during routine metabolic panels.
• Hypocalciuria: A low 24-hour urinary calcium excretion or a low calcium/creatinine clearance ratio (CCCR).
• Normal/Elevated PTH: PTH levels are typically in the upper-normal range or mildly elevated.
• Family History: Often present, but not mandatory (due to de novo mutations).

Diagnostic Workup: The Calcium/Creatinine Clearance Ratio (CCCR)

The CCCR is the gold-standard screening tool to differentiate FHH from PHPT.

Note: The formula uses the calcium and creatinine values from a 24-hour urine collection and a simultaneous serum sample.

3. Differential Diagnosis

Distinguishing FHH from other calcium-related disorders is essential to prevent surgical mismanagement.

• Primary Hyperparathyroidism (PHPT): The primary differential. PHPT patients typically have hypercalciuria, whereas FHH patients have hypocalciuria. PHPT often presents with nephrolithiasis; FHH rarely does.
• Lithium Therapy: Lithium can induce a state pharmacologically identical to FHH by inhibiting the CaSR.
• Vitamin D Deficiency: Can mask the hypercalcemia of FHH, leading to normal serum calcium levels.
• Thiazide Diuretics: Can increase serum calcium and decrease urinary calcium, mimicking FHH.

4. Risks, Side Effects, and Surgical Contraindications

The most significant risk associated with FHH is iatrogenic. Because the condition mimics PHPT, patients are frequently referred for parathyroidectomy.

The Danger of Parathyroidectomy

• Ineffectiveness: Because the hypercalcemia in FHH is a systemic genetic phenomenon (not a parathyroid adenoma), removing the glands does not cure the condition.
• Surgical Complications: Patients face unnecessary risks of vocal cord paralysis (recurrent laryngeal nerve injury), permanent hypoparathyroidism, and scarring.
• Clinical Management: Treatment is almost never indicated for FHH. The condition is benign and does not progress to end-organ damage.

5. Long-Term Prognosis

The prognosis for individuals diagnosed with FHH is excellent. It is a lifelong condition that does not shorten life expectancy.

• Monitoring: Patients require minimal follow-up. Periodic serum calcium checks are sufficient.
• Lifestyle: No specific dietary restrictions are required. Patients should be encouraged to maintain adequate hydration to protect against rare instances of stone formation, although this is not a high risk in FHH.
• Genetic Counseling: Given the autosomal dominant nature, family screening is recommended once an index case is identified.

6. Massive FAQ Section

Q1: Is FHH a disease that requires treatment?

No. FHH is a metabolic variant. It does not require medical or surgical treatment, as the hypercalcemia is "set" at a higher level than normal.

Q2: What is the most common misdiagnosis for FHH?

Primary Hyperparathyroidism (PHPT). Clinicians often panic at the sight of high calcium and elevated PTH and jump to surgery.

Q3: If a patient has FHH, should they take Vitamin D?

Only if they are clinically Vitamin D deficient. However, caution is advised, as increasing Vitamin D levels may worsen the hypercalcemia.

Q4: Does FHH lead to osteoporosis?

Generally, no. Unlike PHPT, which can cause bone mineral density loss, FHH does not typically affect bone structure.

Q5: Is genetic testing necessary for everyone?

It is not mandatory for diagnosis, but it is highly recommended if a patient is considering pregnancy or if the CCCR results are indeterminate.

Q6: Can FHH cause kidney stones?

Rarely. While hypercalcemia is a risk factor for stones, the hypocalciuria in FHH protects the kidneys from stone formation.

Q7: What happens if a patient with FHH undergoes parathyroidectomy?

The patient will likely remain hypercalcemic post-surgery, as the genetic defect remains present in the remaining tissue and other body systems.

Q8: Is FHH passed down to children?

Yes. As an autosomal dominant disorder, there is a 50% chance that an affected parent will pass the gene to each offspring.

Q9: Do patients with FHH need to avoid calcium supplements?

Patients should avoid excessive calcium supplementation, but normal dietary calcium intake is safe and recommended.

Q10: How do I distinguish FHH from Lithium-induced hypercalcemia?

The history is key. If the patient stops taking Lithium, their calcium levels should normalize. If they remain high, FHH is the likely diagnosis.

Summary Table: FHH vs. PHPT

Clinical Conclusion

Familial Hypocalciuric Hypercalcemia represents a classic example of "do no harm" in medicine. The clinical objective is to identify the condition through careful calculation of the CCCR and genetic confirmation, thereby preventing the patient from undergoing unnecessary, expensive, and potentially dangerous surgical intervention. When FHH is diagnosed, the patient should be reassured of its benign nature and managed conservatively.